MOG (myelin oligodendrocyte glycoprotein) is a two-pass type I transmembrane protein belonging to the BTN/MOG family of the immunoglobulin (Ig) superfamily.  MOG contains an Ig-like V-type domain in the first extracelluar region followed by two transmembrane regions and a small second extracellular tail. MOG is found exclusively in the CNS, where it is localized on the surface of myelin and oligodendrogliocyte membranes. The MOG genes are highly conserved in mammals, suggesting an important biological role for this protein.  While the primary molecular function of MOG is not yet known, its likely role with the myelin sheath is either in sheath completion and/or maintenance.  MOG may mediate homophilic cell-cell adhesion. MOG is considered as an autoantigen capable to produce a demyelinating multiple sclerosis (MS)-like disease in experimental animals. Several studies have shown a role for antibodies against MOG in the pathogenesis of MS. The mutation in the MOG gene is associated with Narcolepsy 7 (NRCLP7), a neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis.

MOG (myelin oligodendrocyte glycoprotein) is a two-pass type I transmembrane protein belonging to the BTN/MOG family of the immunoglobulin (Ig) superfamily.  MOG contains an Ig-like V-type domain in the first extracelluar region followed by two transmembrane regions and a small second extracellular tail. MOG is found exclusively in the CNS, where it is localized on the surface of myelin and oligodendrogliocyte membranes. The MOG genes are highly conserved in mammals, suggesting an important biological role for this protein.  While the primary molecular function of MOG is not yet known, its likely role with the myelin sheath is either in sheath completion and/or maintenance.  MOG may mediate homophilic cell-cell adhesion. MOG is considered as an autoantigen capable to produce a demyelinating multiple sclerosis (MS)-like disease in experimental animals. Several studies have shown a role for antibodies against MOG in the pathogenesis of MS. The mutation in the MOG gene is associated with Narcolepsy 7 (NRCLP7), a neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis.

 

Product Details

 

Gene Symbol: MOG; BTN6; BTNL11; MOGIG2; NRCLP7

 

NCBI Gene ID: 4340

 

Uniprot Entry: Q16653

 

Construct Details: The recombinant human MOG-Fc fusion is expressed as a 354 amino acid protein consisting of Gly30 -  Glu145 region of MOG (Uniprot Accession #Q16653) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions.

 

Source:  Human cells stably expressing MOG-Fc growing in chemical-defined media with no animal components or antibiotics 

 

Deduced Amino Acid Sequence:

        10         20         30         40         50         60 

GQFRVIGPRH PIRALVGDEV ELPCRISPGK NATGMEVGWY RPPFSRVVHL YRNGKDQDGD  

        70         80         90        100        110        120 

QAPEYRGRTE LLKDAIGEGK VTLRIRNVRF SDEGGFTCFF RDHSYQEEAA MELKVESTTE 

       130        140        150        160        170        180 

NLYFQGSTGT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV 

       190        200        210        220        230        240 

KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE 

       250        260        270        280        290        300 

KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT  

       310        320        330        340        350 

TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK 

 

M.W.: Calculated molecular mass (kDa): 39.9; Estimated by SDS-PAGE under reducing condition (kDa): 45-50

 

Calculated PI: 6.87 

 

Calculated Extinction Coefficient (M^-1 cm^-1, at 280nm): 48860

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as DTT "+")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier and preservative free). 

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Not available

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C for immediate use. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. J. Neurochem. 63:2353 (1993)

2. J. Neurochem. 65:309 (1994) 

3. J. Neurochem. 72: 1 (1999)

4. N. Engl. J. Med. 349: 139 (2003)

5. Am. J. Hum. Genet. 89:474 (2010)

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL2128-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.